Abstract
The successful execution of clinical trials for novel anti-rheumatic compounds is increasingly approaching the limits of what can be achieved using radiographic outcomes for the assessment of disease modification. Moreover, there is a growing need for more objective tools to assess joint inflammation, especially for disorders such as axial spondyloarthritis where spinal symptoms are often non-specific and physical findings may be minimal until later stages of disease. The use of MRI to evaluate inflammation in the synovium and bone marrow as well as erosions in peripheral joints of patients with RA and PsA represents a major new advance that should now be routinely implemented in clinical trials of RA. MRI-based scoring systems have been well validated and demonstrate that, for RA, MRI changes after therapeutic intervention may be observed in a month and precede findings on radiography that only become evident after a year. The assessment of disease activity on MRI of the sacroiliac joints and spine using a standardized and well-validated method, such as the SPARCC instruments, is indispensable to the evaluation of efficacy for new agents aimed at the treatment of spondyloarthritis. Further advances include the use of whole-body MRI evaluation to assess inflammation in both the axial and peripheral skeleton as well as sequences that dispense with the requirement for the use of contrast agents, such as gadolinium, and data processing techniques that permit full automation and absolute quantification. This review will discuss how imaging is transforming clinical trials in rheumatic diseases.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Proceeding of the Shevchenko Scientific Society. Medical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
